Compare MAIA & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIA | ICG |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 81.1M |
| IPO Year | 2022 | 2022 |
| Metric | MAIA | ICG |
|---|---|---|
| Price | $1.32 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | ★ 655.2K | 185.6K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.93 |
| 52 Week High | $3.19 | $3.22 |
| Indicator | MAIA | ICG |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 49.01 |
| Support Level | $1.20 | $1.15 |
| Resistance Level | $1.47 | $1.36 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 42.04 | 34.09 |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.